Study/author | Public year | Country | Age (year) | Total (I/C)* | Female (%) | follow-up years | Medications used (I/C)* | BP (mmHg) I(SBP/DBP; C(SBP/DBP | Reduction of BP (mmHg)#I(SBP/DBP; C(SBP/DBP) |
---|---|---|---|---|---|---|---|---|---|
UKPDS [19] | 1998 | United Kingdom | 56 | 400/358 | 48 | over 9 | Captopril/Atenolol | 159/94; 159/93 | 15/10; 16/12 |
FACET [11] | 1998 | United State | 63 | 189/191 | 41 | 2.5-3.5 | Fosinopril/Amlodipine | 170/95; 171/94 | 19/8; 13/8 |
RENAAL [23] | 2001 | Multi-centers | 60 | 751/762 | 37 | 3.4 | Losartan/Placebo | 152/82; 153/82 | 12/8; 11/8 |
CAPPP [12] | 2001 | Sweden/Finland | 25–66 | 309/263 | 38 | 6.1 | Captopril/Conventional drugs | 164/97; 163/97 | 8/4; 10/5 |
2001/2003 | Multi-centers | 30-70 | 579/569 | 32 | 2.6 | Irbesartan/Placebo | 160/87; 158/87 | 20/10; 16/7 | |
ADVANCE [13] | 2007 | Multi-centers | 66 | 5,569/5,571 | 43 | 4.3 | Perindopril/Placebo | 145/81; 145/81 | 5.6/2.2# |
CASE-J [21] | 2010 | Japan | 64 | 1,011/1,077 | 44 | 3.3 | Candesartan/Amlodipine | 160/88; 160/88 | --- |
DEMAND [20] | 2011 | Italy/Slovenia | ≥40 | 127/127 | 37 | 3.8 | Delapril/Placebo | 147/87; 147/88 | 11/6; 9/5 |
NHS [22] | 2012 | Japan | 63 | 575/575 | 34 | 3.2 | Valsartan/Amlodipine | 145/82; 144/81 | 14/9; 13/8 |